Otitis Media with Effusion (OME): Avoidance of Topical Intranasal Corticosteroids

Percentage of patients aged 2 months through 12 years with a diagnosis of OME who were not prescribed topical intranasal corticosteroids

AAO 48

Reporting Option: N/A

Quality Domain: Effective Clinical Care

Instructions: N/A

Denominator: All patients aged 2 months through 12 years with a diagnosis of OME

Denominator Criteria (Eligible Cases):
- Patients aged 2 months through 12 years on date of encounter
  AND
  AND
- Patient encounter during the reporting period (CPT)

Denominator Exceptions: Documentation of medical reason(s) for prescribing topical intranasal corticosteroids

Numerator: All patients aged 2 months through 12 years with a diagnosis of OME who were not prescribed topical intranasal corticosteroids

Numerator Quality-Data Coding Options for Reporting Satisfactorily:

Performance Met: Patients who were not prescribed topical intranasal corticosteroids

Medical Performance Exception: Documentation of medical reason(s) for prescribing topical intranasal corticosteroids

Performance Not Met: Patients who were prescribed topical intranasal corticosteroids, reason not otherwise specified

Rationale: OME usually resolves spontaneously with indications for therapy only if the condition is persistent and clinically significant benefits can be achieved. Systemic antimicrobials have no proven long-term effectiveness and have potential adverse effects.

Empowering otolaryngologist–head and neck surgeons to deliver the best patient care
The purpose of the corresponding guideline statement is to reduce ineffective and potentially harmful medical interventions in OME when there is no long-term benefit to be gained in the vast majority of cases. Medications have long been used to treat OME, with the dual goals of improving QOL and avoiding more invasive surgical interventions. Both the 1994 guidelines and the 2004 guidelines determined that the weight of evidence did not support the routine use of steroids (either oral or intranasal), antimicrobials, antihistamines, or decongestants as therapy for OME.

**Clinical Recommendation Statements:** Clinicians should recommend against using intranasal steroids or systemic steroids for treating OME. *Strong recommendation against based on systematic review of RCTs and preponderance of harm over benefit.* [Aggregate evidence quality – Grade A] (AAO-HNSF, 2016)

**Copyright:**

© 2017 American Academy of Otolaryngology – Head and Neck Surgery Foundation. All Rights Reserved.

Limited proprietary coding is contained in the Measure specifications for convenience. Users of the proprietary code sets should obtain all necessary licenses from the owners of these code sets.


The Measures, while copyrighted, can be reproduced and distributed, without modification, for noncommercial purposes, e.g. use by health care providers in connection with their practices. Commercial use is defined as the sale, license, or distribution of the Measures for commercial gain, or incorporation of the Measures into a product or service that is sold, licensed or distributed for commercial gain.

Commercial uses of the Measures require a license agreement between the user and the American Academy of Otolaryngology – Head and Neck Surgery Foundation (AAO-HNSF).

**Disclaimer:**

The Measures are not clinical guidelines, do not establish a standard of medical care, and have not been tested for all potential applications.

THE MEASURES AND SPECIFICATIONS ARE PROVIDED “AS IS” WITHOUT WARRANTY OF ANY KIND. Neither the AAO-HNSF nor its members shall be responsible for any use of the Measures. The AAO-HNSF and its members disclaim all liability for use or accuracy of any Current Procedural Terminology (CPT®) or other coding contained in the specifications.